TLSA
Tiziana Life Sciences Ltd
1.10$
-1.8%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | -1,737.4% | -1,020.4% | -484.7% | -3,359.1% | -1,043.3% | -956.1% | -217.7% | – | – | -3,237.6% | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | 20.2% | 115.7% | 31.4% | 93.1% | 343.1% | 413.8% | 113.4% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | 3.4% | 272.7% | -152.8% | – | – | – | – | 1,154.3% | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | -239.4% | 789.7% | 0.2% | -342.2% | 322.4% | -216.7% | 59.3% | – | – | 2,981.2% | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | 71.7% | 9.8% | 3.0% | 1.1% | 120.7% | 0.0% | 35.8% | – | – | 0.0% | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | -53.5% | -96.9% | -29.9% | -110.6% | -126.9% | -74.3% | -54.5% | – | – | 64.1% | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | 1,669.7% | 1,272.1% | 413.2% | 3,629.4% | 526.5% | 1,044.9% | 298.1% | – | – | 5,000.7% | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | -919.2% | 808.6% | -79.9% | 138.1% | -707.6% | 14.3% | 20.6% | – | – | 1,938.6% | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | -1,809.1% | -1,030.2% | -487.7% | -3,360.2% | -1,043.3% | -956.1% | -253.5% | – | – | -3,237.6% | – | – | – | – | – | – | – | – | – | – | – | – |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.